Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group

Jacquelyn N. Crane; Wei Xue; Amira Qumseya; Zhengya Gao; Carola A.S. Arndt; Sarah S. Donaldson; Douglas J. Harrison; Douglas S. Hawkins; Corinne M. Linardic; Leo Mascarenhas; William H. Meyer; David A. Rodeberg; Erin R. Rudzinski; Barry L. Shulkin; David O. Walterhouse; Rajkumar Venkatramani; Aaron R. Weiss

doi:10.1002/pbc.29644

Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group

Jacquelyn N. Crane, Wei Xue, Amira Qumseya, Zhengya Gao, Carola A.S. Arndt, Sarah S. Donaldson, Douglas J. Harrison, Douglas S. Hawkins, Corinne M. Linardic, Leo Mascarenhas, William H. Meyer, David A. Rodeberg, Erin R. Rudzinski, Barry L. Shulkin, David O. Walterhouse, Rajkumar Venkatramani, Aaron R. Weiss

Pediatric and Adolescent Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.

Original language	English (US)
Article number	e29644
Journal	Pediatric Blood and Cancer
Volume	69
Issue number	6
DOIs	https://doi.org/10.1002/pbc.29644
State	Published - Jun 2022

Keywords

clinical group
rhabdomyosarcoma
stage

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.29644

Cite this

Crane, J. N., Xue, W., Qumseya, A., Gao, Z., Arndt, C. A. S., Donaldson, S. S., Harrison, D. J., Hawkins, D. S., Linardic, C. M., Mascarenhas, L., Meyer, W. H., Rodeberg, D. A., Rudzinski, E. R., Shulkin, B. L., Walterhouse, D. O., Venkatramani, R., & Weiss, A. R. (2022). Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatric Blood and Cancer, 69(6), Article e29644. https://doi.org/10.1002/pbc.29644

Crane, JN, Xue, W, Qumseya, A, Gao, Z, Arndt, CAS, Donaldson, SS, Harrison, DJ, Hawkins, DS, Linardic, CM, Mascarenhas, L, Meyer, WH, Rodeberg, DA, Rudzinski, ER, Shulkin, BL, Walterhouse, DO, Venkatramani, R & Weiss, AR 2022, 'Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group', Pediatric Blood and Cancer, vol. 69, no. 6, e29644. https://doi.org/10.1002/pbc.29644

@article{256c5c423c5f4b3ab95963158cddff6d,

title = "Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group",

abstract = "The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.",

keywords = "clinical group, rhabdomyosarcoma, stage",

author = "Crane, {Jacquelyn N.} and Wei Xue and Amira Qumseya and Zhengya Gao and Arndt, {Carola A.S.} and Donaldson, {Sarah S.} and Harrison, {Douglas J.} and Hawkins, {Douglas S.} and Linardic, {Corinne M.} and Leo Mascarenhas and Meyer, {William H.} and Rodeberg, {David A.} and Rudzinski, {Erin R.} and Shulkin, {Barry L.} and Walterhouse, {David O.} and Rajkumar Venkatramani and Weiss, {Aaron R.}",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = jun,

doi = "10.1002/pbc.29644",

language = "English (US)",

volume = "69",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Clinical group and modified TNM stage for rhabdomyosarcoma

T2 - A review from the Children's Oncology Group

AU - Crane, Jacquelyn N.

AU - Xue, Wei

AU - Qumseya, Amira

AU - Gao, Zhengya

AU - Arndt, Carola A.S.

AU - Donaldson, Sarah S.

AU - Harrison, Douglas J.

AU - Hawkins, Douglas S.

AU - Linardic, Corinne M.

AU - Mascarenhas, Leo

AU - Meyer, William H.

AU - Rodeberg, David A.

AU - Rudzinski, Erin R.

AU - Shulkin, Barry L.

AU - Walterhouse, David O.

AU - Venkatramani, Rajkumar

AU - Weiss, Aaron R.

PY - 2022/6

Y1 - 2022/6

N2 - The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.

AB - The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.

KW - clinical group

KW - rhabdomyosarcoma

KW - stage

UR - http://www.scopus.com/inward/record.url?scp=85125638504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125638504&partnerID=8YFLogxK

U2 - 10.1002/pbc.29644

DO - 10.1002/pbc.29644

M3 - Review article

C2 - 35253352

AN - SCOPUS:85125638504

SN - 1545-5009

VL - 69

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

M1 - e29644

ER -

Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this